[{"orgOrder":0,"company":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","sponsor":"INSERM UMR S1136","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GABON","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida \/ INSERM UMR S1136","highestDevelopmentStatusID":"8","companyTruncated":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida \/ INSERM UMR S1136"},{"orgOrder":0,"company":"Asan Medical Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Undisclosed","graph2":"Phase I","graph3":"Asan Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asan Medical Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Asan Medical Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"IRCCS San Raffaele","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IRCCS San Raffaele","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRCCS San Raffaele \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"IRCCS San Raffaele \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"The HIV Netherlands Australia Thailand Research Collaboration","sponsor":"amfAR | National Health Security Office, Thailand | The Thai Government Pharmaceutical Organization (GPO)","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"The HIV Netherlands Australia Thailand Research Collaboration","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The HIV Netherlands Australia Thailand Research Collaboration \/ amfAR | National Health Security Office, Thailand | The Thai Government Pharmaceutical Organization (GPO)","highestDevelopmentStatusID":"8","companyTruncated":"The HIV Netherlands Australia Thailand Research Collaboration \/ amfAR | National Health Security Office, Thailand | The Thai Government Pharmaceutical Organization (GPO)"},{"orgOrder":0,"company":"St Stephen's AIDS Trust","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"St Stephen's AIDS Trust","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St Stephen's AIDS Trust \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"St Stephen's AIDS Trust \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Hospital Research Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Ottawa Hospital Research Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"National Institute of Allergy and Infectious Diseases | Case Western Reserve University | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ National Institute of Allergy and Infectious Diseases | Case Western Reserve University | Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Cleveland Clinic \/ National Institute of Allergy and Infectious Diseases | Case Western Reserve University | Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Fiocruz research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atazanavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fiocruz research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fiocruz research \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Fiocruz research \/ Undisclosed"},{"orgOrder":0,"company":"Antonella Castagna","sponsor":"Bristol Myers Squibb | ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antonella Castagna","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antonella Castagna \/ Bristol Myers Squibb | ViiV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Antonella Castagna \/ Bristol Myers Squibb | ViiV Healthcare"},{"orgOrder":0,"company":"David Garcia Cinca","sponsor":"Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"David Garcia Cinca","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David Garcia Cinca \/ Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica","highestDevelopmentStatusID":"1","companyTruncated":"David Garcia Cinca \/ Fundaci\u00f3 Cl\u00ednic per a la Recerca Biom\u00e8dica"}]

Find Clinical Drug Pipeline Developments & Deals for Atazanavir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 11, 2022

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Fiocruz research

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Fiocruz research

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Details : Fiocruz research observed that the drug Atazanavir was able to inhibit viral replication and to reduce the production of proteins that are related to the inflammatory process in the lungs in COVID-19.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 09, 2020

                          Lead Product(s) : Atazanavir,Ritonavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 10, 2020

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          David Garcia Cinca

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          David Garcia Cinca

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 12, 2016

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Fundació Clínic per a la Recerca Biomèdica

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          St Stephen's AIDS Trust

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          St Stephen's AIDS Trust

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 28, 2015

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Antonella Castagna

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Antonella Castagna

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 07, 2015

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Bristol Myers Squibb | ViiV Healthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 16, 2015

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : INSERM UMR S1136

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 04, 2014

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Ottawa Hospital Research Institute

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Ottawa Hospital Research Institute

                          Country arrow
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 14, 2014

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Atazanavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Acquired Immunodeficiency Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 20, 2013

                          Lead Product(s) : Atazanavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank